Role of Imaging Bio Marker in Clinical Trials

Brochure available Here !!!

The use of biomarkers in clinical trials can aid operational efficiencies in drug development that as of yet, haven’t been fully realized – arguably, it must be said. But how can biomarkers best be leveraged to reduce timelines and altogether bring drugs faster to market?

An experienced professional, Ruiz is a biomedical engineer who specializes in obtaining imaging biomarkers from medical images with treatment response value. Here, she explains how biomarkers can be incorporated into clinical trials and be fully maximized.

Different biomarkers in Clinical trial

In Clinical trial different types of markers such as biochemical markers, cellular markers, cytokine markers, genetic markers, physiological results, imaging biomarker, neurophysiological biomarker, and proteomics (protein-based biomarkers).

Biomarkers are further classified as target biomarkers (does the drug hit its target and, therefore, provide benefit) and efficacy biomarkers (indicators of positive drug effect via the mechanism of drug action).

Choosing a disease-specific biomarker aid in a more rapid and accurate disease diagnosis; potential reduction in size and duration of the trial, which would in turn speed up the trial submission.

Imaging Biomarker

Imaging biomarkers are very penetrating to small functional or morphological changes that cannot be reported in the radiological qualitative reading during the same time periods since they are not visible to the human eye. Because of that sensitivity in a shorter time, the evolution of the different branches of treatment can be studied in real-time. This helps reduce time while facilitating decision making within clinical trials.

Imaging Biomarker can be

• Anatomical or Functional
• Qualitative or Quantitative

Imaging Biomarkers in Oncology Trials:

Imaging Biomarkers are important to the routine management of patients with cancer. An imaging biomarker is a capacity derived from one or more medical images.

Imaging Biomarker in Neurological Trials

Imaging biomarkers performance a vital role in determining the rate of disease progression in case of Alzheimer’s disease (AD). This permits better tracking of changes over a period of pathoanatomic or pathophysiologic modifications in the brain as seen in cases of the AD

Imaging biomarker in Musculoskeletal trails:
Radiological endpoints in clinical trials for the valuation of the musculoskeletal system are several and have a unique set of challenges that are usually disease specific.